Insider · CIK 0001640869
Nancy Denyes
Files at ATYR (aTYR PHARMA INC). First filing Feb 4, 2025, latest Feb 4, 2026.
In brief
Nancy Denyes files SEC Form 4 as officer at ATYR (aTYR PHARMA INC). Since Feb 4, 2025, Nancy Denyes has reported 0 open-market buys worth $0 and 2 open-market sells worth $4,490, the latest filed on Feb 4, 2026.
A track record needs three past buys with six months of prices behind them; Nancy Denyes has 0, so none is measured yet.
The newest scored trade: sold $1,091 of ATYR on Feb 4, 2026, filed Feb 4, 2026, scored 15 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $1,091.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ATYR: aTYR PHARMA INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | aTYR PHARMA INC | $1,091 1,118 shares | -3% | +35% from low-87% from high | |
| 8Weak | aTYR PHARMA INC | $3,398 899 shares | -3% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | ATYR aTYR PHARMA INC | MOption exercise Common Stock | +2,687 | - | - | 34,242 | Feb 4, 2026 |
| Feb 4, 2026 | ATYR aTYR PHARMA INC | SOpen-market sale Common Stock | -1,118 | $0.98 | $1,091 | 33,124 | Feb 4, 2026 |
| Feb 3, 2026 | ATYR aTYR PHARMA INC | MOption exercise Restricted Stock Unitderivative | -2,687 | $0.00 | $0 | 0 | Feb 4, 2026 |
| Jan 9, 2026 | ATYR aTYR PHARMA INC | AGrant or award Employee Stock Options (right to buy)derivative | +412,500 | $0.00 | $0 | 412,500 | Jan 9, 2026 |
| Feb 3, 2025 | ATYR aTYR PHARMA INC | MOption exercise Common Stock | +2,687 | - | - | 27,454 | Feb 4, 2025 |
| Feb 4, 2025 | ATYR aTYR PHARMA INC | SOpen-market sale Common Stock | -899 | $3.78 | $3,398 | 26,555 | Feb 4, 2025 |
| Feb 3, 2025 | ATYR aTYR PHARMA INC | MOption exercise Restricted Stock Unitderivative | -2,687 | $0.00 | $0 | 2,687 | Feb 4, 2025 |
| Jan 8, 2025 | ATYR aTYR PHARMA INC | AGrant or award Employee Stock Option (right to buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Jan 10, 2025 |
| Feb 5, 2024 | ATYR aTYR PHARMA INC | MOption exercise Common stock | +2,688 | - | - | 14,767 | Feb 6, 2024 |
| Feb 5, 2024 | ATYR aTYR PHARMA INC | MOption exercise Restricted Stock Unitderivative | -2,688 | $0.00 | $0 | 5,374 | Feb 6, 2024 |
| Jan 5, 2024 | ATYR aTYR PHARMA INC | AGrant or award Employee Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jan 9, 2024 |
Questions about Nancy Denyes
Answered from the filings on this page, as of the latest one.
Is Nancy Denyes buying or selling?
In the last 12 months Nancy Denyes reported 0 open-market buys worth $0 and 1 open-market sell worth $1,091 on SEC Form 4; the latest was sold $1,091 of ATYR on Feb 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Nancy Denyes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nancy Denyes has 0.
Where does Nancy Denyes file Form 4?
Nancy Denyes has filed Form 4 at ATYR (aTYR PHARMA INC) as General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.